Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iTOL-200 is a 50-micron microgel developed by iTolerance, Inc. It is designed to be co-administered with a liver cell therapy to form iTOL-201. The primary goal of this therapy is to enable ectopic liver implantation without the need for chronic immunosuppression, thereby preventing graft rejection. The microgel is based on the same concept as iTOL-100 and incorporates SA-FasL microgels, suggesting a mechanism aimed at inducing immune tolerance. Early *in vitro* data indicated no significant impact on the survival of hepatocytes when co-administered with SA-FasL microgels. The next developmental step involves evaluating iTOL-201 in preclinical animal models of liver transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iTOL-200.